Bradley Canino
Stock Analyst at Stifel
(1.05)
# 3,481
Out of 4,829 analysts
94
Total ratings
25.93%
Success rate
-13.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $1.75 | +757.14% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $0.44 | +244.67% | 8 | Mar 7, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $3.11 | +639.55% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $6.52 | +682.21% | 6 | Feb 12, 2025 | |
| JANX Janux Therapeutics | Maintains: Buy | $70 → $115 | $26.06 | +341.29% | 2 | Dec 3, 2024 | |
| AFMD Affimed | Maintains: Hold | $5 → $4 | $0.69 | +477.20% | 5 | Nov 15, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $41 | $10.99 | +273.07% | 5 | Oct 14, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $6.09 | +212.24% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $10.68 | +293.44% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $25.26 | +58.35% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $73.63 | +83.35% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $5.41 | +269.69% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.15 | +769.57% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.29 | +675.19% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $42.41 | +133.44% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $1.58 | +786.08% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $7.91 | +405.69% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $130 | $100.27 | +29.65% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $32.17 | +70.97% | 4 | Feb 23, 2024 |
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $1.75
Upside: +757.14%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $0.44
Upside: +244.67%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $3.11
Upside: +639.55%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $6.52
Upside: +682.21%
Janux Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $70 → $115
Current: $26.06
Upside: +341.29%
Affimed
Nov 15, 2024
Maintains: Hold
Price Target: $5 → $4
Current: $0.69
Upside: +477.20%
Syndax Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $40 → $41
Current: $10.99
Upside: +273.07%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $6.09
Upside: +212.24%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $10.68
Upside: +293.44%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $25.26
Upside: +58.35%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $73.63
Upside: +83.35%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $5.41
Upside: +269.69%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $1.15
Upside: +769.57%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.29
Upside: +675.19%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $42.41
Upside: +133.44%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $1.58
Upside: +786.08%
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $7.91
Upside: +405.69%
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $100.27
Upside: +29.65%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $32.17
Upside: +70.97%